Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Analysts at Raymond James decreased their FY2024 earnings per share (EPS) estimates for Oncolytics Biotech in a research note issued on Tuesday, November 12th. Raymond James analyst R. Sarugaser now forecasts that the company will earn ($0.32) per share for the year, down from their prior estimate of ($0.28). The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.29) per share. Raymond James also issued estimates for Oncolytics Biotech's Q4 2024 earnings at ($0.09) EPS, Q1 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.
Separately, HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price target on shares of Oncolytics Biotech in a report on Thursday.
View Our Latest Stock Analysis on ONCY
Oncolytics Biotech Stock Performance
Shares of NASDAQ ONCY traded down $0.03 during mid-day trading on Friday, hitting $0.98. The stock had a trading volume of 245,250 shares, compared to its average volume of 328,224. Oncolytics Biotech has a twelve month low of $0.84 and a twelve month high of $1.75. The firm has a market cap of $75.53 million, a PE ratio of -3.63 and a beta of 1.69. The company has a 50 day moving average of $1.09 and a two-hundred day moving average of $1.06.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC bought a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 51,889 shares of the company's stock, valued at approximately $55,000. Virtu Financial LLC owned about 0.07% of Oncolytics Biotech at the end of the most recent reporting period. 6.82% of the stock is owned by institutional investors.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Read More
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
